

Revised Draft Agenda
Biocides Working Group Meeting II-2019
19-29 March 2019

ECHA Conference Centre (Annankatu 18)
 Meeting room Margot Wallstrom (MW)
 Meeting room Guido Sacconi (GS)
 Meeting room Marie Curie (MC)
 Meeting room K325

Coffee break 11:00-11:30
 Lunch break 13:00-14:00
 Coffee break 15:30-16:00

Tuesday 19 March	09:00-13:00	APCP WG (K325)
	14:00-18:00	
Tuesday 26 March	09:00-13:00	TOX WG (MW)
	14:00-18:00	
Wednesday 27 March	09:00-13:00	TOX WG (MW)
	14:00-18:00	
Thursday 28 March	09:00-13:00	TOX WG (MC - C)
Wednesday 27 March	09:00-13:00	EFF WG (GS)
	14:00-18:00	
Thursday 28 March	09:00-13:00	EFF WG (GS)
	14:00-18:00	
Friday 29 March	09:00-13:00	EFF WG (GS)
	14:00-16:00	
Wednesday 27 March	09:30-13:00	EG Meeting on PT 8 (K325) – only for assigned experts
	14:00-18:00	
Thursday 28 March	09:00-13:00	ENV WG (MC - A)
	14:00-18:00	
Friday 29 March	09:00-13:00	ENV WG (MC - A)
	14:00-16:00	

Analytical methods and physico-chemical properties Working Group		
Chair: Bernhard Krebs		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement of the draft minutes from WG-VI-2018 and WG-VII-2018		
<ul style="list-style-type: none"> • <i>WG VI 2018_APCP_5-1</i> • <i>WG VI 2018_APCP_5-2</i> • <i>WG VI 2018_APCP_5-3</i> • <i>WG VI 2018_APCP_5-4</i> • <i>WG VI 2018_APCP_gen agenda</i> • <i>WG VII 2018_APCP_5-1</i> • <i>WG VII 2018_APCP_5-2</i> • <i>WG VII 2018_APCP_5-3</i> • <i>WG VII 2018_APCP_5-4</i> • <i>WG VII 2018_APCP_gen agenda</i> 		<i>For agreement</i>
Item 6 - Discussion of Union Authorisation applications		eCA
6.1	UA for product family Permethrin/S-Methoprene PT 18 Meeting document: <i>WG II 2019_APCP_6-1</i>	FR <i>For agreement</i>
6.2	UA for product family containing Octanoic acid PT 04 Meeting document: <i>WG II 2019_APCP_6-2</i>	NL <i>For agreement</i>
6.3	UA for product family containing Octanoic acid/Decanoic acid PT 04 Meeting document: <i>WG II 2019_APCP_6-3</i>	BE <i>For agreement</i>
6.4	UA for product family containing Hydrogen peroxide PT 01, 02, 03, 04 Meeting document: <i>WG II 2019_APCP_6-4</i>	LV <i>For agreement</i>

Item 7 – Shelf-life decision tree		
7.1	Shelf-life decision tree Meeting document: <i>WG II 2019_APCP_7</i> <i>For discussion</i>	FR
Item 8 – Outcome of e-consultations		
8.1-8.3	Outcome of e-consultations Meeting document: <i>WG II 2019_APCP_8-1, WG II 2019_APCP_8-2, WG II 2019_APCP_8-3</i> <i>For information</i>	
Item 9 - AOB		

Efficacy Working Group		
Chair: Katarzyna Szymankiewicz		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement of the draft minutes from WG-I-2019 • <i>WG-I-2019_EFF_6-1</i>		<i>For agreement</i>
Item 6 - Discussion of Union Authorisation applications		eCA
6.1	UA for product family containing Hydrogen peroxide PT 01-04 Meeting document: <i>WGII2019_EFF_6-1</i>	LV <i>For agreement</i>
6.2	UA for product family containing Octanoic acid/Decanoic acid PT 04 Meeting document: <i>WGII2019_EFF_6-2</i>	BE <i>For agreement</i>
6.3	UA for product family containing Octanoic acid PT 04 Meeting document: <i>WGII2019_EFF_6-3</i>	NL <i>For agreement</i>
6.4	UA for product family Permethrin/S-Methoprene PT 18 Meeting document: <i>WGII2019_EFF_6-4</i>	FR <i>For agreement</i>
Item 7 - Technical and guidance related issues		CA
7.1	Vol. II, Parts B+C – PT1-5, Appendix 4 Meeting document: <i>WGII2019_EFF_7-1</i>	ECHA <i>For discussion</i>
7.2	Vol. II, Parts B+C – draft guidance PT11/12 Meeting document: <i>WGII2019_EFF_7-2</i>	FR <i>For discussion</i>

7.3	<p>Vol. II, Parts B+C – draft guidance PT19</p> <p>a. Mosquito – AIC simulated-use test Meeting document: <i>WGII2019_EFF_7-3.a</i> <i>For discussion</i></p> <p>b. Mortality outcome of the e-consultation Meeting document: <i>WGII2019_EFF_7-3.b</i> <i>For discussion</i></p> <p>c. Ticks Meeting document: <i>WGII2019_EFF_7-3.c</i> <i>For discussion</i></p> <p>d. Ants Meeting document: <i>WGII2019_EFF_7-3.d</i> <i>For discussion</i></p>	DE
Item 8 - AOB		
8.1	<p>Outcome of e-consultations</p> <p>a. Growth quantification or determination of filamentous fungi (FR) Meeting document: <i>WGII2019_EFF_8-1.a</i> <i>For discussion</i></p> <p>b. Paint layer thickness in static raft tests (NL) Meeting document: <i>WGII2019_EFF_8-1.b</i> <i>For discussion</i></p> <p>c. Efficacy assessment of hatching eggs (DE) Meeting document: <i>WGII2019_EFF_8-1.c</i> <i>For discussion</i></p>	MSs
8.2	<p>Other information & lessons learned Meeting document: <i>WGII2019_EFF_8-2</i></p>	ECHA

Human Health Working Group		
Chair: Antero Airaksinen		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement of the draft minutes from WG-VII-2018		
<ul style="list-style-type: none"> • WG-VII-2018_TOX_6-1 • WG-VII-2018_TOX_6-2 • WG-VII-2018_TOX_6-3 • WG-VII-2018_TOX_6-4 • WG-VII-2018_TOX_6-5 • WG-VII-2018_TOX_Minutes 		<i>For agreement</i>
Item 6 - Discussion of Union Authorisation applications		eCA
6.1	UA for product family containing Hydrogen peroxide PT 01-04 Meeting document: <i>WGII2019_TOX_6-1</i> <div style="text-align: right;"><i>For agreement</i></div>	LV
6.2	UA for product family containing Octanoic acid/Decanoic acid PT 04 Meeting document: <i>WGII2019_TOX_6-2</i> <div style="text-align: right;"><i>For agreement</i></div>	BE
6.3	UA for product family containing Octanoic acid PT 04 Meeting document: <i>WGII2019_TOX_6-3</i> <div style="text-align: right;"><i>For agreement</i></div>	NL
6.4	UA for product family Permethrin/S-Methoprene PT 18 Meeting document: <i>WGII2019_TOX_6-4</i> <div style="text-align: right;"><i>For agreement</i></div>	FR
Item 7 - Discussion of Active Substances		eCA
7.1	DBNPA ED assessment Meeting document: <i>WGII2019_TOX_7-1</i> <div style="text-align: right;"><i>For agreement</i></div>	DK

7.2	Sulfur dioxide generated from sulfur by combustion PT 04 Meeting document: <i>WGII2019_TOX_7-2</i> <i>For agreement</i>	DE
7.3	Sulfur dioxide released from sodium metabisulfite PT 09 Meeting document: <i>WGII2019_TOX_7-3</i> <i>For agreement</i>	DE
Item 8 - Technical and guidance related issues		Presenter
8.1	Update on guidance development Meeting document: <i>WGII2019_TOX_8-1</i> <i>For discussion</i>	SECR
8.2	HEAdhoc: PT 18 professional exposure scenarios Meeting document: <i>WGII2019_TOX_8-2</i> <i>For agreement</i>	DE
8.3	Dermal absorption of a repellent used together with sunscreen/sun lotion products Meeting document: <i>WGII2019_TOX_8-3</i> <i>For discussion</i>	SE
8.4	Harmonising the use of default dermal absorption values derived according to EFSA (2017) Meeting document: <i>WGII2019_TOX_8-4</i> <i>For agreement</i>	DE
8.5	Updating the WG recommendation for in situ generated active substances and their precursors Meeting document: <i>WGII2019_TOX_8-5</i> <i>For discussion</i>	SECR
8.6	Read-across for biocides Meeting document: <i>WGII2019_TOX_8-6</i> <i>For information</i>	SECR
Item 9 – AOB		Presenter
9.1	Other information & lessons learned Meeting document: <i>WGII2019_TOX_9-1</i> <i>For discussion</i>	SECR
9.2	Active substance workshop: Feedback and actions Meeting document: <i>WGII2019_TOX_9-2</i> <i>For discussion</i>	SECR

Environment Working Group Chair: Heike Schimmelpfennig		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement of the draft minutes from WG-VII-2018		<i>For information</i>
Item 6 - Discussion of Union Authorisation applications		eCA
6.1	UA for product family containing Hydrogen peroxide PT 01-04 Meeting document: <i>WGII2019_ENV_6-1</i> <div style="text-align: right;"><i>For agreement</i></div>	LV
6.2	UA for product family containing Octanoic acid/Decanoic acid PT 04 Meeting document: <i>WGII2019_ENV_6-2</i> <div style="text-align: right;"><i>For agreement</i></div>	BE
6.3	UA for product family containing Octanoic acid PT 04 Meeting document: <i>WGII2019_ENV_6-3</i> <div style="text-align: right;"><i>For agreement</i></div>	NL
6.4	UA for product family Permethrin/S-Methoprene PT 18 Meeting document: <i>WGII2019_ENV_6-4</i> <div style="text-align: right;"><i>For agreement</i></div>	FR
Item 7 - Discussion of Active Substances		eCA
7.1	DBNPA ED assessment Meeting document: <i>WGII2019_ENV_7-1</i> <div style="text-align: right;"><i>For agreement</i></div>	DK
7.2	Feedback on ongoing & finalised substance specific e-consultations Meeting document: <i>WGII2019_ENV_7-2</i> <div style="text-align: right;"><i>For information</i></div>	NL/SECR

7.3	Pyrethroid metabolites harmonised LoEP – update Meeting document: <i>WGII2019_ENV_7-3</i> <i>For discussion</i>	DE/SECR
Item 8 – Technical and guidance related items		Presenter
8.1	Overview on guidance SECR to inform <i>For information</i>	SECR
8.2	Outcome EPM project SECR to inform <i>For information</i>	SECR
8.3	RMM for bees (e-consultation) Meeting document: <i>WGII2019_ENV_8-3</i> <i>For discussion</i>	SECR
8.4	Report back: Workshop Extrapolation across biological level SECR to inform <i>For information</i>	SECR
Item 9 – AOB		Presenter
9.1	Other information & lessons learned Meeting document: <i>WGII2019_ENV_9-1</i> <i>For information</i>	SECR
9.2	Active substance workshop: Feedback and actions Meeting document: <i>WGII2019_ENV_9-2</i> <i>For discussion</i>	SECR

o0o